Multicomponent intraocular lens implantation: Two-year follow-up

PurposeTo report the 2-year follow-up of the initial clinical evaluation of Infinite Vision Optics multicomponent intraocular lens (IOL) implantation.SettingInstitute of Vision and Optics, University of Crete, Crete, Greece.DesignCase series.MethodsAll patients had routine cataract surgery and multicomponent IOL implantation. The primary objectives of the study were to evaluate the manufacturing feasibility of the IOL, the evaluation of the surgical implantation technique, and the incidence of interlenticular fibrosis.ResultsThis initial clinical evaluation comprised 6 patients with a mean age of 63.3 years ± 12.7 (SD) (range 49 to 82 years). Implantations were uneventful in all cases. There were no intraoperative or postoperative complications. There was no interlenticular fibrosis. There was no statistically significant difference in the endothelial cell density, anterior chamber depth, or pachymetry readings between preoperatively and 2 years postoperatively. No patient lost lines of corrected distance visual acuity.ConclusionsMulticomponent IOL implantation was easy and safe and resulted in excellent visual recovery. No cases of interlenticular fibrosis developed.Financial DisclosureDr. Portaliou has received travel grant and meeting expenses from Infinite Vision Optic. Neither of the other 2 authors has a financial or proprietary interest in any material or method mentioned.